Guo Yong-Zhi, Jiang Ying-Nan, Li Yi-Fang, Kurihara Hiroshi, Dai Yi, He Rong-Rong
Guangdong Province Research and Development Center for Chinese Medicine in Disease Susceptibility, College of Pharmacy, Jinan University, Guangzhou, China.
International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), College of Pharmacy, Jinan University, Guangzhou, China.
Front Pharmacol. 2020 Jan 22;10:1564. doi: 10.3389/fphar.2019.01564. eCollection 2019.
Chinese medicine is a national treasure that has been passed down for thousands of years in China. According to the statistics of the World Health Organization, there are currently four billion people in the world who use Chinese medicine to treat diseases, accounting for 80% of the world's total population. However, the obscurity of its theory, its unmanageable quality, its complex compositions, and the unknown effective substances and mechanisms are great obstacles to the internationalization of Chinese medicine. Here, we propose a new strategy for the development of Chinese medicine: the clinical prescription (C)-protein (P)-small-molecule (S)-disease (D) strategy, namely the CPSD strategy. The strategy uses clinical prescriptions as the source of medicine and uses computer simulation technology to find small-molecule drugs targeting therapeutic proteins for treating specific diseases so as to deepen awareness of the value of Chinese medicine. At the same time, this article takes cardiovascular drug development as an example to introduce the application of CPSD, which will be instrumental in the further development, modernization, and internationalization of Chinese medicine.
中医是中国传承了数千年的瑰宝。据世界卫生组织统计，目前全球有40亿人使用中医治病，占世界总人口的80%。然而，其理论晦涩、质量难以把控、成分复杂以及有效物质和作用机制不明，是中医国际化的巨大障碍。在此，我们提出一种中医发展的新策略：临床处方（C）-蛋白质（P）-小分子（S）-疾病（D）策略，即CPSD策略。该策略以临床处方为药物来源，利用计算机模拟技术寻找针对治疗特定疾病的治疗性蛋白质的小分子药物，以加深对中医价值的认识。同时，本文以心血管药物研发为例介绍CPSD的应用，这将有助于中医的进一步发展、现代化和国际化。
